Driving Depression Care Forward by Optimizing Quality Measures
Millions of Americans suffer from Major Depressive Disorder (MDD), but the U.S. health care system is not adequately detecting, assessing, or treating many people with this disease. Quality measurement is one tool that can help drive better depression care through improved screening, monitoring, and outcome assessment. As such, developing appropriate quality measurement tools spanning structure to outcomes assessment, coupled with the effective use of the data collected, are critical to improving care for people with MDD.
In an effort to advance MDD quality measurement and treatment, Leavitt Partners, in collaboration with Takeda and Lundbeck, convened a roundtable of experts to review existing quality measures related to MDD treatment to identify gaps in those measures and their use. Roundtable participants in the October 2017 meeting included a diverse group of individuals from both public and private organizations who provided unique and varied viewpoints throughout the discussion.